TIDMIXI
IXICO plc
02 June 2016
IXICO announces that its real world digital data collection
study, project Cygnus, has joined Dementias Platform UK, and has
initiated all sites and enrolled first subjects
2 June 2016, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'),
the brain health company, is pleased to announce that Cygnus, a
real world digital data collection study from people with cognitive
impairment and dementia, has joined the high profile Dementias
Platform UK (DPUK).
The four NHS Trusts participating in the project have now
initiated enrolment in the mehealth(R) digital technology platform
which is being deployed for data collection and management.
Consumer wearable devices containing accelerometers will also be
deployed to collect information on sleep and activity. The Cygnus
study aims to advance the development of digital healthcare in
patients with cognitive impairment and dementia and their
caregivers.
By joining Dementias Platform UK, Cygnus is now part of a high
profile collaborative project that includes leading academic
centres and pharmaceutical companies GSK, AstraZeneca and Johnson
& Johnson. IXICO's mehealth(R) platform is being used for data
collection from participating services and patients and their
caregivers. The mehealth(R) digital technology platform formed part
of the Optimal Medicine acquisition in December 2015.
Professor Derek Hill, Chief Executive of IXICO, commented:
"We believe digital technologies will improve the lives of both
people with cognitive impairment and dementia and their families,
potentially transforming how treatments are developed and
delivered. The IXICO sponsored Cygnus project is now using such
technologies in community memory services in the North of England.
We are pleased our recently-acquired mehealth(R) platform is
supporting this project in partnership with global pharmaceutical
companies within the Dementias Platform UK."
Professor John Gallacher, Director of Dementias Platform UK
commented:
"We are delighted that IXICO's Cygnus cohort is contributing
data into the secure DPUK data portal. Not only does this support
the open science vision of the Dementias Platform, but it
transforms the way that industry and academic collaborations can be
used to develop innovative treatments. We are particularly excited
that Cygnus is pioneering the use of digital technologies including
mobile devices and wearables to bring a real world evidence
emphasis to the DPUK data portal."
Enquiries:
IXICO plc +44 20 3763 7499
Derek Hill, CEO
Susan Lowther, CFO
Peel Hunt LLP (Nominated
Adviser and Broker)
James Steel / Oliver Jackson +44 20 7418 8900
Daniel Stewart & Company
(Joint Broker)
Martin Lampshire / David
Coffman +44 207 776 6550
FTI Consulting Limited
(Investor Relations)
Simon Conway / Mo Noonan
/ Matthew Moss +44 20 3727 1000
Notes to Editors
About IXICO
IXICO's innovative and proprietary digital healthcare
technologies help those involved in researching and treating
serious diseases to capture and analyse clinical data to make
rapid, informed decisions. In clinical research this includes the
phenotyping of patients, quantification of disease pathology and
measurement of patient outcomes. In clinical practice the mobile
health and digital decision support technologies aid diagnosis,
patient engagement and monitoring. IXICO is also collaborating with
partners to develop companion digital health products targeted at
improving patient outcomes.
The Company's brain health focus includes Alzheimer's disease,
Huntington's disease, multiple sclerosis, behavioural health, child
and adolescent mental health.
More information is available on www.ixico.com
About mehealth(R)
The mehealth(R) platform integrates web-based and mobile
technologies for clinicians, patients and care-givers for use in
both clinical care and clinical trial settings. In clinical
practice it allows care to be initiated and adapted according to
the patients' unique profile and evolving needs. The software has
been used in the care of over 12,000 children with ADHD across the
US and has been shown in a randomised trial to improve concordance
with clinical guidelines. In clinical trials mehealth enables the
collection of data from multiple environments and informants,
including the integration of remote monitoring wearables,
smartphone applications and patient- and caregiver-facing web-based
portals.
More information is available on www.mehealth.com
About the Cygnus project
Cygnus is a two year project funded by Innovate UK and brings
together four Mental Health Trusts in the North of England, the
Northern Health Science Alliance (NHSA), IXICO and the
International Consortium for Health Outcomes Measures (ICHOM). The
project is the first implementation of the recently published ICHOM
dementia standard dataset.
The Mental Health Trusts and lead investigators participating in
the project are:
-- Manchester Health and Social Care Trust / University of Manchester
-- Mersey Care
-- Tee, Esk and Wear Valleys NHS Foundation Trust
-- Northumberland, Tyne and Wear NHS Foundation Trust
The project aims to enrol 500 participants: patients referred to
Memory Assessment Services at the participant Trusts with suspected
dementia and their caregivers.
Key objectives of the Cygnus study are:
-- To evaluate the feasibility of web-based, mobile and wearable
technologies as a means to collect high quality and actionable data
from patients and their care givers;
-- Linking these measurements to data about outcomes and
episodes of care;
-- To provide a well-characterised population who have consented
to contact about future evaluation of technologies and
interventions that might benefit patients and caregivers.
More information is available on www.ecygnus.com
About DPUK
Established by the Medical Research Council in June 2014, DPUK
is a GBP53 million collaboration between universities and drug
companies to transform the best dementia research into the best
treatments as quickly as possible.
It combines the power of different types of population study to
compare healthy people with people at all stages of dementias and
can be used to look at how this is affected by other conditions
that people may have.
It actively encourages leading researchers to work together,
giving them better access to the wealth of information on health
and lifestyle through huge population studies and arms them with
the latest technology, to scan the body and brain and analyse
tests.
It also spearheads 'experimental medicine' research, which are
'first in human' studies, testing out new treatments, new devices,
improvements in diagnoses for the first time in people and also
looking at repurposing drugs - trying out treatments which are
already on the market, but used for a different condition, to see
how they might benefit those with dementia. DPUK forms a central
pillar in the delivery of the UK Prime Minister's Challenge on
dementia.
More information is available on www.dementiasplatform.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASSUSIEFMSELM
(END) Dow Jones Newswires
June 02, 2016 02:00 ET (06:00 GMT)
Phytopharm (LSE:PYM)
Historical Stock Chart
From Nov 2024 to Dec 2024
Phytopharm (LSE:PYM)
Historical Stock Chart
From Dec 2023 to Dec 2024
